CommercialCoverageMedium impact
Intensity-Modulated Radiotherapy (IMRT): Cancer of the Head and Neck or Thyroid
Blue Cross & Blue Shield of Mississippi·MS · Oncology, Radiology, ENT (Ear, Nose & Throat)·Medical Policy
We identified it
Jun 20, 2026
Summary
Blue Cross Blue Shield of Mississippi updated their policy for Intensity-Modulated Radiotherapy (IMRT) for head and neck or thyroid cancers. IMRT is considered medically necessary for head and neck cancers, and for thyroid cancers only when close to organs at risk and 3D-CRT cannot meet dose constraints.
Action Required
Immediately: Billing team must ensure proper documentation for IMRT claims. For head and neck cancers, verify cancer location includes oral cavity, lip, larynx, hypopharynx, oropharynx, nasopharynx, paranasal sinuses, nasal cavity, salivary glands, or occult primaries. For thyroid cancers, require documentation that cancer is near organs at risk (esophagus, salivary glands, spinal cord) and that 3D-CRT cannot meet dose constraints. Claims for thyroid IMRT without meeting these criteria will be denied as investigational.